Treatment of Post-transplant Relapse of FLT3-ITD Mutated AML Using 5-Azacytidine and Sorafenib Bitherapy

With the recent progress of allogenic stem cell transplantation (allo-SCT), more patients with acute myeloid leukemia (AML) have access to allo-SCT and mortality has decreased.1 However, 30%-40% of patients relapse, outcome after post-transplant relapse is poor, and most patients do not benefit from salvage chemotherapy. Approximately one-third of these patients harbor Fms-like tyrosine kinase 3 (FLT3) internal tandem duplication (ITD), which is associated with sensitivity to several tyrosine kinase inhibitors.

Source: Clinical Lymphoma, Myeloma and Leukemia - January 9, 2017 Category: Hematology Authors: Sid Selim, Jerome Rey, Aude Charbonnier, Evelyne D'Incan, Bilal Mohty, Didier Blaise, Norbert Vey Tags: Letter to the Editor Source Type: research